Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

H.C. Wainwright has recently reiterated Microbot Medical Inc (MBOT) stock to Buy rating, as announced on January 13, 2020, according to Finviz. Earlier, on December 24, 2019, H.C. Wainwright had ...

H.C. Wainwright reaffirmed its Buy rating on Cybin Inc. (NYSE:CYBN) with a steady price target of $190.00, significantly above the current trading price of $9.59. With a market capitalization of $192 ...

Personalis (NASDAQ:PSNL – Free Report) had its price objective decreased by HC Wainwright from $11.00 to $8.00 in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright ...

Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for Genmab A/S in a report issued on ...

H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $190 price target on Cybin (CYBN) shares, telling investors in a research ...

On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88. The firm's ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...

H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...